International Journal of Radiation Oncology * Biology * Physics
Volume 82, Issue 2 , Pages 877-882 , 1 February 2012

Long-Term Outcomes From a Prospective Trial of Stereotactic Body Radiotherapy for Low-Risk Prostate Cancer

This paper was presented at the 52nd Annual Meeting of the American Society for Radiation OncologySan Diego Convention Center, San Diego, CA. November 2010

  • Christopher R. King, Ph.D., M.D.

      Affiliations

    • Departments of Radiation Oncology and Urology, University of California Los Angeles School of Medicine, Los Angeles, CA
    • Corresponding Author InformationReprint requests to: Christopher R. King, Ph.D., M.D., Department of Radiation Oncology, UCLA School of Medicine, 200 UCLA Medical Plaza, Los Angeles, CA 90095. Tel: (310) 825-9775; FAX: (310) 794-9795
    • ,
  • James D. Brooks, M.D.

      Affiliations

    • Department of Urology, Stanford University School of Medicine, Stanford, CA
    • ,
  • Harcharan Gill, M.D.

      Affiliations

    • Department of Urology, Stanford University School of Medicine, Stanford, CA
    • ,
  • Joseph C. Presti Jr., M.D.

      Affiliations

    • Department of Urology, Stanford University School of Medicine, Stanford, CA

Received 18 August 2010 ,Revised 25 October 2010 ,Accepted 2 November 2010.

References 

  1. Dasu A. Is the α/β value for prostate tumours low enough to be safely used in clinical trials?. Clin Oncol. 2007;19:289–301
  2. Fowler JF, Ritter MA, Chappell RJ, Brenner DJ. What hypofractionated protocols should be tested for prostate cancer?. Int J Radiat Oncol Biol Phys. 2003;56:1093–1104
  3. Yeoh EE, Holloway RH, Fraser RJ, et al. Hypofractionated vs. conventionally fractionated radiation therapy for prostate carcinoma: Updated results of a Phase III randomized trial. Int J Radiat Oncol Biol Phys. 2006;66:1072–1083
  4. Lukka H, Hayter C, Julian JA, et al. Randomized trial comparing two fractionation schedules for patients with localized prostate cancer. J Clin Oncol. 2005;23:6132–6138
  5. Kupelian PA, Willoughby TR, Reddy CA, et al. Hypofractionated intensity-modulated radiotherapy (70 Gy at 2.5 Gy per fraction) for localized prostate cancer: Cleveland Clinic experience. Int J Radiat Oncol Biol Phys. 2007;68:1424–1430
  6. Livsey JE, Cowan RA, Wylie JP, et al. Hypofractionated conformal radiotherapy in carcinoma of the prostate: Five-year outcome analysis. Int J Radiat Oncol Biol Phys. 2003;57:1254–1259
  7. Lloyd-Davies RW, Collins CD, Swan AV. Carcinoma of prostate treated by radical external beam radiotherapy using hypofractionation. Twenty-two years’ experience (1962–1984). Urology. 1990;36:107–111
  8. Yoshioka Y, Konishi K, Sumida I, et al. Monotherapeutic high-dose-rate brachytherapy for prostate cancer: Five-year results of an extreme hypofractionation regimen with 54 gy in nine fractions. Int J Radiat Oncol Biol Phys. In press.
  9. Martinez AA, Demanes J, Vargas C, et al. High-dose-rate prostate brachytherapy: An excellent accelerated-hypofractionated treatment for favorable prostate cancer. Am J Clin Oncol. 2010;33:481–488
  10. Madsen BL, Hsi RA, Pham HT, et al. Stereotactic hypofractionated accurate radiotherapy of the prostate (SHARP), 33.5 Gy in five fractions for localized prostate disease: First clinical trial results. Int J Radiat Oncol Biol Phys. 2007;67:1099–1105
  11. King CR, Brooks JD, Gill H, et al. Stereotactic body radiotherapy for localized cancer: Interim results of a prospective Phase II clinical trial. Int J Radiat Oncol Biol Phys. 2009;73:1043–1048
  12. Katz AJ, Santoro M, Ashley R, et al. Stereotactic body radiotherapy for organ-confined prostate cancer. BMC Urol. 2010;10:1
  13. Townsend NC, Huth BJ, Ding W, et al. Acute toxicity after CyberKnife-delivered hypofractionated radiotherapy for treatment of prostate cancer. Am J Clin Oncol. In press.
  14. Greene FL, Page DL, Flemming ID, et al. AJCC Manual for staging cancer. 6th ed.. New York: Springer Verlag; 2002;p. 309–313
  15. Common toxicity criteria (Version 2.0). Bethesda, MD: National Institutes of Health; 1998;
  16. Peeters STH, Heemsbergen WD, Koper PCM, et al. Dose–Response in radiotherapy for localized prostate cancer: Results of the Dutch Multicenter Randomized Phase III Trial comparing 68 Gy of radiotherapy with 78 Gy. J Clin Oncol. 2006;24:1990–1996
  17. Kuban DA, Tucker SL, Dong L, et al. Long-term results of the M.D. Anderson randomized dose-escalation trial for prostate cancer. Int J Radiat Oncol Biol Phys. 2008;70:67–74
  18. Zietman AL, Bae K, Slater JD, et al. Randomized trial comparing conventional-dose with high-dose conformal radiation therapy in early-stage adenocarcinoma of the prostate: Long-term results from Proton Radiation Oncology Group/American College of Radiology 95-09. J Clin Oncol. 2010;28:1106–1111
  19. Dearnley DP, Sydes MR, Graham JD, et al. Escalated-dose versus standard-dose conformal radiotherapy in prostate cancer: First RESULTS from the MRC RT01 Randomized Controlled Trial. Lancet Oncol. 2007;8:475–487
  20. Kupelian PA, Willoughby TR, Reddy C, et al. Hypofractionated intensity-modulated radiotherapy (70 Gy at 2.5 Gy per fraction) for localized prostate cancer: Cleveland Clinic experience. Int J Radiat Oncol Biol Phys. 2007;68:1424–1430
  21. Martin JM, Rosewall T, Bayley A, et al. Phase II trial of hypofractionated image-guided intensity modulated radiotherapy for localized prostate adenocarcinoma. Int J Radiat Oncol Biol Phys. 2007;69:1084–1089
  22. Coote JH, Wylie JP, Cowan RA, et al. Hypofractionated intensity-modulated radiotherapy for carcinoma of the prostate: Analysis of toxicity. Int J Radiat Oncol Biol Phys. 2009;74:1121–1127
  23. Lock M, Best L, Wong E, et al. A Phase II trial of arc-based hypofractionated intensity-modulated radiotherapy in localized prostate cancer. Int J Radiat Oncol Biol Phys. In press
  24. Zelefsky MJ, Chan H, Hunt M, et al. Long-term outcome of high dose intensity modulated radiation therapy for patients with clinically localized prostate cancer. J Urol. 2006;176:1415–1419
  25. Elliott SP, Meng MV, Elkin EP, et al. Incidence of urethral stricture after primary treatment for prostate cancer: Data from CaPSURE. J Urol. 2007;178:529–534
  26. Katz MS, Efstathiou JA, D’Amico AV, et al. The “CaP Calculator”: An online decision support tool for clinically localized prostate cancer. BJU Int. 2010;105:1417–1422

 Conflict of interest: none.

PII: S0360-3016(10)03677-1

doi: 10.1016/j.ijrobp.2010.11.054

International Journal of Radiation Oncology * Biology * Physics
Volume 82, Issue 2 , Pages 877-882 , 1 February 2012

Article Tools

* Image Usage & Resolution